iCo Therapeutics Featured in JDRF's Top Research Highlights Publication

VANCOUVER, July 3, 2012 /CNW/ - iCo Therapeutics (TSX-V: ICO), a Vancouver-based drug company, is pleased to announce that it has been featured in a JDRF newsletter entitled Top Research Highlights. JDRF is the largest charitable supporter of type 1 diabetes (T1D) and has joined forces with iCo Therapeutics to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema (DME).  The iDEAL study is a Phase II clinical trial to evaluate the drug iCo-007 as a treatment for DME. The study is being conducted at a leading US medical institution and 25 additional sites across the United States.

Top Research Highlights is a quarterly newsletter published by JDRF to highlight new treatments and research for T1D and related complications. A copy of this newsletter may be viewed at:

http://www.jdrf.org/files/General_Files/Get_Involved/TopResearch_Spring2012.pdf

Commented Andrew Rae, President and CEO of iCo Therapeutics: "It is an honor to be featured in the latest publication of Top Research Highlights. JDRF is the largest funder of diabetes research in the world and has a mandate to inform and educate patients, donors and the public on the latest developments in diabetes, including diabetic complications. We appreciate JDRF and its keen interest in supporting our work in DME."

About iCo-007
Designed and discovered by ISIS Pharmaceuticals Inc., (NASDAQ: ISIS), iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the treatment of DME and diabetic retinopathy.  iCo-007 completed an open label, dose escalating Phase I trial with safety as the primary endpoint, and visual acuity and measures of retinal thickness serving as secondary endpoints.  Importantly, iCo saw no drug-related serious adverse events, no signs of ocular inflammation, no intraocular pressure issues and no systemic exposure. In August 2011, iCo announced the initiation of a US physician-sponsored Phase II clinical trial involving iCo-007, titled the iDEAL study, which is being conducted across multiple sites throughout the United States. The iDEAL Study is being led by the clinician scientists who are investigators in the trial and is being coordinated at a leading US medical institution.

About DME (Diabetic Macular Edema)
DME is the swelling of the retina in diabetes patients due to leaking blood vessels within the macula, the central portion of the retina that is critical for daytime vision. DME is the leading cause of blindness in working-age adults and affects approximately 1.6 million people in the United States alone, a number that is expected to grow as diabetes is forecast to increase by almost 50 percent in the United States by 2025.

About T1D
In T1D, a person's pancreas stops producing enough insulin to survive. People with T1D must currently monitor their blood sugar levels and administer insulin via shots or an insulin pump, multiple times every day. Even vigilant management does not ward against T1D complications such as heart attack, stroke, blindness, and amputation.

About JDRF
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is the largest charitable supporter of T1D research. The goal of JDRF is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal. Since its founding in 1970, JDRF has awarded more than $1.6 billion to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. Past JDRF research efforts have helped to significantly improve the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. For more information, please visit www.jdrf.org.

About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications.   iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011.     iCo trades on the TSX Venture Exchange under the symbol "ICO". For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this release.  The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

SOURCE iCo Therapeutics Inc.

For further information:

iCo Finance
Mr. John Meekison, CFO
604-602-9414 x 224
meekison@icotherapeutics.com 

Equicom Group
Michael Moore, Investor Relations
619-467-7067
mmoore@equicomgroup.com
Shaun Smith, Media Relations
416-815-0700 x252
ssmith@equiomgroup.com 

Crescendo Communications
David Waldman/Klea Theoharis
212-671-1021
ico@crescendo-ir.com

Profil de l'entreprise

iCo Therapeutics Inc.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.